Consequently, the CXCR4/CXCL12 signaling pathway may impair CAR T‐cell infiltration and suppress effector function within stromal‐supported regions, thereby limiting therapeutic efficacy in CLL. Here, CXCL12 is linked to B-cell chronic lymphocytic leukemia.